Results 181 to 190 of about 18,181 (226)

Safety and effectiveness of rituximab biosimilar (Rituximab-GP2013) versus originator in rheumatoid arthritis: real-world evidence from a single center. [PDF]

open access: yesClinics (Sao Paulo)
Bayeh B   +16 more
europepmc   +1 more source

A model for the clinical management of the introduction of new medicines in a large University Hospital in Spain. [PDF]

open access: yesJ Pharm Policy Pract
Danés I   +10 more
europepmc   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Biosimilars

Lupus, 2020
Biological therapies have widened the therapeutic armamentarium for immune-mediated inflammatory diseases, providing in many cases a broad range of treatment options with different mechanisms of action. The widespread use of biological agents in systemic lupus erythematosus is currently limited to belimumab and rituximab, although results of promising ...
Christopher J Edwards   +1 more
  +5 more sources

Biosimilarity Assessment of Biosimilar Therapeutic Monoclonal Antibodies

open access: yesDrug Metabolism and Pharmacokinetics, 2019
The concept of biosimilar was established in the early 2000s in EU. Currently, the regulatory framework for biosimilar has also been established in the US, Japan, and other countries. As of 2018, biosimilars for infliximab, adalimumab, rituximab, trastuzumab, and bevacizumab have been approved.
Takashi Kuwabara
exaly   +3 more sources

Biosimilar medicines

European Journal of Hospital Pharmacy, 2019
Biological medicines have become indispensable in the treatment of patients with serious diseases such as cancer and inflammatory diseases. Biosimilars are medicines which are developed to be similar to existing biological medicines (the 'reference product'). For the European market, they are approved by the European Medicines Agency.
András Süle   +4 more
openaire   +2 more sources

The Role of Biosimilars

Journal of the National Comprehensive Cancer Network, 2016
As biologics go off-patent, the field of oncology is grappling with incorporating biosimilars. These are highly similar (but not generic versions of) biologic agents, and they are approved based on showing "near fingerprint identity" in structure and potency. Their introduction is expected to increase competition and lower treatment costs.
Andrew D, Zelenetz, Pamela S, Becker
openaire   +2 more sources

The rise of the biosimilar

Expert Review of Clinical Pharmacology, 2012
Recombinant biologics have had an incredible impact on diseases such as arthritis and cancer by targeting specific receptors or disease mediators; however, access to these drugs is increasingly lim...
Mark, McCamish, Gillian, Woollett
openaire   +2 more sources

Home - About - Disclaimer - Privacy